Journal Information
Vol. 38. Issue. 5.September - October 2018
Pages 459-572
Vol. 38. Issue. 5.September - October 2018
Pages 459-572
Letter to the Editor
DOI: 10.1016/j.nefroe.2018.07.004
Open Access
Prevalence of symptoms in advanced chronic kidney disease
Prevalencia de síntomas en enfermedad renal crónica avanzada
Visits
1236
Daniel Gutiérrez Sáncheza,b, Juan P. Leiva-Santosc, María José Macías Lópezd, Antonio I. Cuesta-Vargasb,
Corresponding author
acuesta@uma.es

Corresponding author.
a Fundación Cudeca, Arroyo de la Miel, Málaga, Spain
b Departamento de Fisioterapia, Instituto de Investigación Biomédico de Málaga (IBIMA), Universidad de Málaga, Málaga, Spain
c Hospital de Manacor, Mallorca, Islas Baleares, Spain
d Servicio de Nefrología, Hospital Regional Universitario de Málaga, Málaga, Spain
This item has received
1236
Visits

Under a Creative Commons license
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (1)
Table 1. Sociodemographic and clinical characteristics of the total group and the subgroups.
Full Text
Dear Editor,

Patients with advanced chronic kidney disease (ACKD) present a wide range of symptoms with a high treatment cost.1 From the initial stages of ACKD, the symptoms are wide-ranging and negatively affect quality of life.1 Uncontrolled symptoms in this population contribute to greater suffering and symptomatic management is a priority.2 The lack of studies conducted in Spain makes it impossible to compare the symptomology between the different treatment groups.

The aim of this study was to describe the prevalence and severity of symptoms in patients with CKD stage 4 and 5 on dialysis and pre-dialysis, and to compare the symptomology in both groups.

In this cross-sectional, observational study, a descriptive analysis was conducted on the prevalence and intensity of symptoms in patients with ACKD, both on dialysis and pre-dialysis. The study data were collected between April and September 2015.

The inclusion criteria were as follows: (1) adult patients with CKD stage 4–5 in pre-dialysis or dialysis for more than 3 months; and (2) Spanish-speaking patients. Patients with cognitive impairment and those under 18 years of age were excluded.

Sociodemographic and clinical data were collected during the interviews, which took place during the ACKD consultation and in the dialysis room. Variables of interest such as symptomology, measured using the modified Spanish version of the Palliative Care Outcome Scale-Symptoms Renal (POS-S Renal), estimated glomerular filtration rate, measured using CKD-EPI, and estimated comorbidity, measured using the modified Charlson comorbidity index (mCCI), are included.3–5

A total of 180 patients with CKD stage 4 and 5 were included in this study, of which 124 patients were on pre-dialysis and 56 were on dialysis (44 haemodialysis and 12 peritoneal dialysis). The results are shown in Table 1. The main comorbidities were: diabetes, ischaemic heart disease, peripheral vascular disease and malignancies.

Table 1.

Sociodemographic and clinical characteristics of the total group and the subgroups.

Characteristics  Total  Pre-dialysis  Dialysis  p 
Patients (n)  180  124  56   
Age (years)  66.3 (14.6)  69.8 (12.6)  58.7 (15.9)  <0.001 
Gender        0.031 
Male (%)  65  70.2  53.6  0.031 
Female (%)  35  29.8  46.4  0.031 
eGFR CKD-EPI ml/min/1.73m2  13.7 (16.9)  17 (5.7)  6.6 (2.6)  <0.001 
Haematocrit (%)  36 (5.2)  36.6 (4.7)  34.7 (5.9)  0.028 
Serum albumin, g/dl  3.9 (0.4)  3.9 (0.4)  3.9 (0.3)  0.585 
Time on MRC or dialysis (months)  31.8 (27.1)  27.5
(17.9) 
41.3 (39.1)  0.001 
Causes of CKD        0.240 
Vascular disease (%)  35  42.7  17.9  0.001 
Diabetic nephropathy (%)  13.9  14.5  12.5  0.719 
Glomerular disease (%)  8.9  6.5  14.3  0.088 
Polycystic kidney disease (%)  6.7  5.6  8.9  0.416 
Unknown aetiology (%)  11.7  12.1  10.7  0.791 
Other causes (%)  23.8  18.5  35.7  0.012 

The most common symptoms were: weakness (68.7% [CI: 22–76%]), pain (53.1% [CI: 45–61%]), depression (45% [CI: 36–51%]) and difficulty sleeping (44.4% [CI: 37–53%]). Significant differences were found in the prevalence of symptoms between pre-dialysis and dialysis for weakness (p=0.027), limited mobility (p=0.018), drowsiness (p=0.03), constipation (p=0.015) and restless legs (p<0.01). The comparison of the prevalence of symptoms between pre-dialysis and dialysis is shown in Fig. 1. The most severe symptoms were: weakness (18.8%), pain (14.6%) and pruritus (11.8%).

Fig. 1.

Prevalence of symptoms in the pre-dialysis and dialysis subgroups.

Difference between groups: *p<0.05.

(0.18MB).

There are several factors such as kidney failure, associated comorbidity and renal replacement therapy (RRT) that can influence the symptomology in these patients.6

More than 44% of patients presented weakness, pain, depression and difficulty sleeping. These symptoms are consistent in the majority of studies and are associated with a poorer quality of life.1 Symptoms such as weakness, limited mobility, drowsiness, constipation and restless legs presented a significant difference in both groups, being more common in patients on dialysis (except constipation).

Weakness is a very common symptom of ACKD. Various factors, such as sleep disorders, depression, anaemia and RRT can influence the onset of this symptom.1 Weakness was the most prevalent and severe symptom, and was more prevalent in dialysis (p=0.02).

Limited mobility is associated with weakness, comorbidity and RRT. Impaired mobility after starting RRT is associated with short-term mortality in elderly patients.7 In this study, limited mobility was more common in patients with RRT (p=0.01).

Regarding daytime drowsiness, this is associated with other sleep disorders (sleep apnoea, insomnia, and restless leg syndrome), and with symptoms such as weakness and depression.8 Various factors, such as psychological disorders, lifestyle, treatment and comorbidity can influence the onset of this problem.8 The results indicate that daytime drowsiness was more common in patients on dialysis (p=0.03).

Constipation is a common problem in ACKD, and is associated with dietary restrictions, limited mobility and pharmacological treatment.9 This symptom was more prevalent in pre-dialysis patients (p=0.01).

Restless legs syndrome is associated with RRT and other sleep disorders, leading to a reduced quality of life.10 This problem was more common in the dialysis group (p0.01).

This study has several limitations. It is a cross-sectional study conducted in a single centre and, therefore, the results cannot be generalised. Furthermore, the pre-dialysis and dialysis groups were not homogenous.

We concluded that patients with ACKD presented a higher symptom burden. In general, there is a similar symptomatic profile in pre-dialysis and dialysis, with weakness being the most common symptom in both groups.

References
[1]
S.N. Davison, A. Levin, A.H. Moss, V. Jha, E.A. Brown, F. Brennan, et al.
Executive summary of the KDIGO controversies conference on supportive care in chronic kidney disease: developing a roadmap to improving quality care.
Kidney Int, 88 (2015), pp. 447-459
[2]
B. Manns, B. Hemmelgarn, E. Lillie, S.C. Dip, A. Cyr, M. Gladish, et al.
Setting research priorities for patients on or nearing dialysis.
Clin J Am Soc Nephrol, 9 (2014), pp. 1813-1821
Available from: https://www.ncbi.nlm.nih.gov/pubmed/24832095 [accessed 15.12.16]
[3]
D. Gutiérrez-Sánchez, J.P. Leiva-Santos, R. Sánchez-Hernández, D. Hernández-Marrero, A.I. Cuesta-Vargas.
Spanish modified version of the palliative care outcome scale-symptoms renal: cross-cultural adaptation and validation.
BMC Nephrol, 17 (2016), pp. 180
Available from: https://www.ncbi.nlm.nih.gov/pubmed/27863475 [accessed 12.12.16]
[4]
R. Montañés Bermúdez, J. Bover Sanjuán, A. Oliver Samper, J.A. Ballarín Castán, S. Gràcia García.
[Assessment of the new CKD-EPI equation to estimate the glomerular filtration rate].
Available from: https://www.ncbi.nlm.nih.gov/pubmed/20038962 [accessed 02.01.17]
[5]
S. Beddhu, F.J. Bruns, M. Saul, P. Seddon, M.L. Zeidel.
A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients.
Am J Med, 108 (2000), pp. 609-613
Available from: https://www.ncbi.nlm.nih.gov/pubmed/10856407 [accessed 15.11.16]
[6]
M.A. Brown, S.M. Crail, R. Masterson, C. Foote, J. Robins, I. Katz, et al.
ANZSN renal supportive care 2013: Opinion pieces [corrected].
Nephrology (Carlton), 18 (2013), pp. 401-454
Available from: https://www.ncbi.nlm.nih.gov/pubmed/23586687 [accessed 12.11.16]
[7]
Y. Arai, E. Kanda, H. Kikuchi, C. Yamamura, S. Hirasawa, S. Aki, et al.
Decreased mobility after starting dialysis is an independent risk factor for short-term mortality after initiation of dialysis.
Nephrology (Carlton), 19 (2014), pp. 227-233
Available from: https://www.ncbi.nlm.nih.gov/pubmed/24397310 [accessed 02.02.17]
[8]
S.C. Maung, A. El Sara, C. Chapman, D. Cohen, D. Cukor.
Sleep disorders and chronic kidney disease.
World J Nephrol, 5 (2016), pp. 224-232
Available from: https://www.ncbi.nlm.nih.gov/pubmed/27152260 [accessed 10.01.17]
[9]
A. Lee, K. Lambert, P. Byrne, M. Lonergan.
Prevalence of constipation in patients with advanced kidney disease.
J Ren Care, 42 (2016), pp. 144-149
Available from: https://www.ncbi.nlm.nih.gov/pubmed/27113374 [accessed 22.01.17]
[10]
M.Z. Molnar, M. Novak, L. Szeifert, C. Ambrus, A. Keszei, A. Koczy, et al.
Restless legs syndrome, insomnia, and quality of life after renal transplantation.
J Psychosom Res, 63 (2007), pp. 591-597
Available from: https://ncbi.nlm.nih.gov/pubmed/18061749/ [accessed 25.07.17]

Please cite this article as: Gutiérrez Sánchez D, Leiva-Santos JP, Macías López MJ, Cuesta-Vargas AI. Prevalencia de síntomas en enfermedad renal crónica avanzada. Nefrologia. 2018;38:560–562.

Copyright © 2018. Sociedad Española de Nefrología
Idiomas
Nefrología (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.